Ann Arbor-based
Meditrina Pharmaceuticals Inc.
was awarded $4.4 million in start-up funds that will allow the company
to proceed with a Phase 2 clinical trial for a drug that might be used
to treat several women's health issues.
Excerpt:
Meditrina is currently enrolling women in a United States-based, multi-center, placebo-controlled study that will evaluate the appropriate time during the menstrual cycle in which to initiate dosing in premenopausal women to either induce or maintain a thin endometrium. The issue of timing during the menstrual cycle is crucial in order to progress into a subsequent phase II dose ranging trial (M002), as well as a larger pivotal phase III trial (M003), the latter of which is scheduled to commence in early 2008.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.